, and pancreatic polypeptide (PP) when given just before a meal."-'" Impaired postprandial gall bladder contraction is a risk factor for gall stone formation.1 '16 We examined the effect of varying the intervals between octreotide injection and meal ingestion on fasting and postprandial gall gladder motility and on plasma CCK and PP concentrations in patients with acromegaly. These findings were used to see whether appropriate timing of octreotide injections with respect to meal ingestion might avert impaired gall bladder contraction. In addition, we examined the effect of CSOI on fasting and postprandial gall bladder motility and hormone release in these patients.
Patients and methods

SUBJECTS
Six patients with active acromegaly, requiring octreotide treatment, were enrolled in the study. All patients had typical clinical features of the acromegaly syndrome, high circulating growth hormone concentrations, which were not suppressed below 2 pg/l after an oral glucose load, and insulin like growth factor-I (IGF-1) or somatomedin-C plasma concentrations above the mean 2 (SD) for age. Table I shows patient characteristics. Ultrasound examination of the gall bladder, bile ducts, and liver was performed before the study and showed no stones, sludge, or other abnormalities. None of the patients had had abdominal surgery previously. None of the patients were pregnant at the time of the study or had taken any drug which could potentially interfere with gall bladder motility. Body weight was stable during the three months preceding the study. All Time (min) Figure 1 : Gall bladder volume before and after a test meal duringfive experimental conditions. *= before treatment, 0-45 minutes after injection of 100 kg octreotide, A =4 hours after injection, + =8 hours after injection, A -durnng continuous subcutaneous octreotide infusion of300 kg124 hfor two weeks.
ml. Forty five minutes and four hours after subcutaneous octreotide injection (measured on separate days), postprandial gall bladder contraction was stopped. Eight hours after octreotide injection, postprandial gall bladder contraction was partially restored. Fasting gall bladder volume increased after injections, compared with the volume before treatment. After two weeks of CSOI of 300 Rg/24 h, fasting gall bladder volume had increased almost twofold to 81L5 (9 2) ml whereas postprandial gall bladder contraction was 50-8 (8-5)% or 39-7 (6-3) ml. Eight hours after injection of octreotide and after two weeks of CSOI, AVmax ml (as index for the amount of bile expelled to the duodenum during a meal) was not significantly different compared with that of gall bladder contraction without treatment (Fig 2) . CHOLECYSTOKININ AND PP RELEASE Table III shows indices of plasma CCK and PP release. Basal CCK concentrations did not change during octreotide treatment. Postprandial CCK release was suppressed for at least four hours after injection (Fig 3) . Eight hours after injection, integrated postprandial CCK release was not significantly different compared with the first measurement, without treatment (Fig 4) . During CSOI, postprandial CCK release was suppressed. Integrated CCK release was only 46-0 ( 22 5) intermittent injections as well as by CSOI (Fig 5) .
PLASMA OCTREOTIDE CONCENTRATION Table III shows plasma octreotide concentrations. As expected, plasma octreotide concentrations were lowest eight hours after injection. During CSOI, octreotide concentrations were comparable with values at four hours after injection. Octreotide concentrations during CSOI did not change for two hours after meal consumption (results not shown).
Discussion
This study showed that fasting gall bladder volume increased after treatment with octreotide. Fasting gall bladder volume had virtually doubled from 42 1 ml in octreotide free conditions to 81-5 ml after two weeks of CSOI. Increased fasting gall bladder volume during octreotide might be a result of decreased gall bladder muscle tone or because of the absence of interdigestive gall bladder contraction, which takes place in the fasting state, in close association with the intestinal migrating motor complex.23 Decreased sphincter of oddi function might also account for increased fasting volume. 24 In comparison with a control group of 20 normal subjects, studied in our laboratory, patients with acromegaly had large fasting volumes, even without treatment (18 *9 (1 6 ml) v 4241 (6-3 ml); p<0002).25 Similarly, increased fasting gall bladder volumes have been reported in obese, tall, and muscular subjects.26 Therefore, increased fasting volumes in patients with acromegaly might be explained by their large body size. We found that patients with acromegaly not receiving treatment, were able to contract their gall bladder almost completely after a meal. This is in agreement with other studies.2 27 It would seem that acromegaly as such does not directly impair gall bladder contraction. Our study also showed that postprandial gall bladder contraction was suppressed for at least four hours after octreotide injection. Delayed gastric emptying is not responsible for this finding since octreotide, in contrast with somatostatin, slightly accelerates gastric emptying of a mixed meal.28 Like others, we saw postprandial gall bladder filling rather than contraction at 45 minutes and four hours after injection. 12 At eight hours after injection, postprandial gall bladder contraction (ml) was not significantly different compared with contraction without treatment or with contraction after two weeks of CSOI. This could be because of the small number of patients studied, but it is in agreement with the results of Hopman et al, who measured postprandial gall bladder contraction in patients on longterm (six months) intermittent injection treatment. At eight hours after the last injection they found 17-0 ml emptying, which was not significantly different from postprandial gall bladder contraction without treatment. 27 Low plasma octreotide concentration and increased fasting volume may explain improved gall bladder contraction. Gall bladder contraction during longterm treatment was still greatly Acromegaly patients generally use three octreotide injections daily, usually given before breakfast in the morning (8:00), afternoon (16:00), and late in the evening (24:00). This study suggests that if the early morning injection is taken after breakfast, the gall bladder can empty partially (43-4%). Gall bladder contraction during lunch and dinner (within 4 to 6 hours of the early morning and afternoon injection), however, remains suppressed. Good gall bladder contraction after breakfast is important because gall bladder bile has the highest cholesterol saturation index and concentration at that time and cholesterol crystals might precipitate easily.4' In the subgroup of patients who are treated with two injections daily, adequate gall bladder contraction might also be achieved after dinner. At eight hours after injection, about 70% of maximum gall bladder contraction was achieved at 45 minutes after the test meal. This might suggest that octreotide injections should be given at least 45 minutes after a meal. During CSOI, postprandial gall bladder contraction is partially preserved during all meals.
In conclusion, this study shows that postprandial gall bladder contraction and CCK and PP release are greatly impaired for at least four hours after injection of octreotide. Eight hours after octreotide injection, gall bladder contraction is partially restored and CCK release is completely restored. Also during CSOI, postprandial gall bladder contraction is partially restored while CCK release remains low. Prospective studies should show whether appropriate timing of octreotide injections with respect to meal ingestion, or alternative treatment schedules, like CSOI, might lessen the risk of gall stone formation during long term octreotide treatment. 
